FDA approved Immgolis (golimumab-sldi) as an interchangeable biosimilar to Simponi for Accord BioPharma.
What this means
Immgolis is a biosimilar version of Simponi, a biologic drug that blocks TNF-alpha, a protein involved in inflammation, to treat conditions like rheumatoid arthritis and Crohn’s disease. FDA approved Immgolis as interchangeable with Simponi, meaning pharmacists can substitute it without consulting the prescribing doctor. This approval could increase access to a lower-cost treatment option for patients managing chronic inflammatory diseases.
